## Malak S Abedalthagafi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8036339/publications.pdf

Version: 2024-02-01

110 papers 3,025 citations

186265 28 h-index 52 g-index

120 all docs

120 docs citations

times ranked

120

5048 citing authors

#	Article	IF	CITATIONS
1	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	1.2	83
2	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. Journal of Infection and Public Health, 2022, 15, 142-151.	4.1	10
3	Correlation between ABO Blood Group Phenotype and the Risk of COVID-19 Infection and Severity of Disease in a Saudi Arabian Cohort. Journal of Epidemiology and Global Health, 2022, 12, 85-91.	2.9	10
4	Association of KIR gene polymorphisms with COVID-19 disease. Clinical Immunology, 2022, 234, 108911.	3.2	15
5	Index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes. European Journal of Human Genetics, 2022, 30, 392-393.	2.8	2
6	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	7.7	52
7	Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients. Oncotarget, 2021, 12, 686-697.	1.8	5
8	Epigenomics and immunotherapeutic advances in pediatric brain tumors. Npj Precision Oncology, 2021, 5, 34.	5.4	9
9	Improving the completeness of public metadata accompanying omics studies. Genome Biology, 2021, 22, 106.	8.8	22
10	Diversity in immunogenomics: the value and the challenge. Nature Methods, 2021, 18, 588-591.	19.0	40
11	Editorial: Genomics and Epigenomics of Cancer Immunotherapy: Challenges and Clinical Implications. Frontiers in Oncology, 2021, 11, 704397.	2.8	O
12	Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	56
13	Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary, 2021, 24, 359-373.	2.9	12
14	The clinico-pathologic profile of primary and recurrent orbital/periorbital plexiform neurofibromas (OPPN). PLoS ONE, 2021, 16, e0258802.	2.5	0
15	The History and Challenges of Women in Genetics: A Focus on Non-Western Women. Frontiers in Genetics, 2021, 12, 759662.	2.3	5
16	Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study. European Journal of Ophthalmology, 2021, , 112067212110662.	1.3	0
17	Fabrication of a Lateral Flow Assay for Rapid In-Field Detection of COVID-19 Antibodies Using Additive Manufacturing Printing Technologies. International Journal of Bioprinting, 2021, 7, 399.	3.4	8
18	Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Genomics, 2020, 112, 1746-1753.	2.9	10

#	Article	IF	CITATIONS
19	iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Research, 2020, 288, 198129.	2.2	226
20	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Frontiers in Neurology, 2020, 11, 544680.	2.4	16
21	Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in lowâ€resource settings. Pediatric Blood and Cancer, 2020, 67, e28309.	1.5	10
22	Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions. Frontiers in Neurology, 2020, 11, 167.	2.4	7
23	Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy. Genetics in Medicine, 2020, 22, 1598-1605.	2.4	18
24	Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib. JCO Precision Oncology, 2020, 4, 796-800.	3.0	13
25	Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population. Npj Genomic Medicine, 2020, 5, 3.	3.8	24
26	Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. PLoS ONE, 2020, 15, e0228356.	2.5	9
27	Immunophenotype of Vestibular Schwannomas. Otology and Neurotology, 2020, 41, e1290-e1296.	1.3	9
28	Molecular Taxonomy of Meningioma. , 2020, 81, .		0
29	RARE-55. CHALLENGES AND SPECIFIC STRATEGIES FOR CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME IN LOW RESOURCE SETTINGS. ON BEHALF OF THE INTERNATIONAL RRD CONSORTIUM IN LOW RESOURCE SETTINGS PANEL. Neuro-Oncology, 2020, 22, iii454-iii454.	1.2	O
30	MBCL-01. METHYLATION PROFILING OF PEDIATRIC MEDULLOBLASTOMA IN SAUDI ARABIA IN A CLINICAL SETTING PERMITS SUB-CLASSIFICATION AND REVEALS NEW OUTCOME PREDICTIONS. Neuro-Oncology, 2020, 22, iii386-iii387.	1.2	0
31	LGG-01. CLINICAL MANAGEMENT AND GENOMIC PROFILING OF PEDIATRIC LOW-GRADE GLIOMAS IN SAUDI ARABIA. Neuro-Oncology, 2020, 22, iii366-iii366.	1.2	0
32	LGG-15. PEDIATRIC LOW-GRADE GLIOMAS IN SAUDI ARABIA: RETROSPECTIVE ANALYSIS OF CHILDREN WITH LOW-GRADE GLIOMAS TREATED IN KING FAHAD MEDICAL CITY KFMC- SINGLE INSTITUTIONAL EXPERIENCE. Neuro-Oncology, 2020, 22, iii368-iii369.	1.2	0
33	HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB. Neuro-Oncology, 2020, 22, iii345-iii345.	1.2	0
34	PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION. Neuro-Oncology, 2020, 22, ii172-ii172.	1.2	0
35	Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. , 2020, 15, e0228356.		0
36	Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. , 2020, 15, e0228356.		0

#	Article	IF	CITATIONS
37	Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. , 2020, 15, e0228356.		О
38	Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. , 2020, 15, e0228356.		0
39	LGG-03. NEW INSIGHTS INTO PEDIATRIC LOW-GRADE GLIOMAS IN SAUDI ARABIA REVEALED THROUGH GENETIC PROFILING SINGLE CENTER EXPERIENCE. Neuro-Oncology, 2019, 21, ii99-ii99.	1.2	0
40	Recent Advances in Meningioma Immunogenetics. Frontiers in Oncology, 2019, 9, 1472.	2.8	42
41	New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses. Oncotarget, 2019, 10, 5549-5559.	1.8	16
42	Precsion medicine of monogenic disorders Lessons learned from the Saudi human genome. Frontiers in Bioscience - Landmark, 2019, 24, 870-889.	3.0	14
43	Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro-Oncology, 2018, 20, 1331-1343.	1.2	9
44	HGG-03. PREVALENCE OF BIALLELIC MISMATCH REPAIR DEFICIENCY IN CHILDREN WITH MALIGNANT GLIOMA TREATED AT KING FAHAD MEDICAL CITY (KFMC). Neuro-Oncology, 2018, 20, i89-i89.	1.2	0
45	Rare TP53 variant associated with Li-Fraumeni syndrome exhibits variable penetrance in a Saudi family. Npj Genomic Medicine, 2018, 3, 35.	3.8	6
46	MBRS-01. A CASE OF MOLECULARLY PROFILED EXTRANEURAL MEDULLOBLASTOMA METASTASES IN A CHILD. Neuro-Oncology, 2018, 20, i128-i128.	1.2	0
47	Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies. Oncotarget, 2018, 9, 35458-35469.	1.8	47
48	Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. Oncologist, 2018, 23, 1401-1406.	3.7	53
49	Immunogenetics of glioblastoma: the future of personalized patient management. Npj Precision Oncology, 2018, 2, 27.	5.4	23
50	Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls. Acta Neuropathologica Communications, 2018, 6, 107.	5.2	7
51	As a Saudi woman scientist, l'm tired of negative stereotypes. Nature, 2018, 554, 405-405.	27.8	1
52	A case of molecularly profiled extraneural medulloblastoma metastases in a child. BMC Medical Genetics, 2018, 19, 10.	2.1	3
53	IMMU-01. DURABLE RESPONSE TO NIVOLUMAB IN A PEDIATRIC PATIENT WITH REFRACTORY GLIOBLASTOMA AND CONSTITUTIONAL BIALLELIC MISMATCH REPAIR DEFICIENCY. Neuro-Oncology, 2018, 20, i98-i98.	1.2	0
54	A Jordanian biologist redefines success for women in science. Nature, 2018, 560, 164-164.	27.8	1

#	Article	lF	Citations
55	Craniopharyngioma: a roadmap for scientific translation. Neurosurgical Focus, 2018, 44, E12.	2.3	26
56	Immune Microenvironment of Vestibular Schwannomas. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.8	1
57	Immune Microenvironment of Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.8	O
58	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
59	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology, 2017, 158, 2284-2291.	2.8	53
60	Genomic landscape of high-grade meningiomas. Npj Genomic Medicine, 2017, 2, .	3.8	130
61	Lymph node metastasis of presacral ependymoblastoma in a young child. Journal of Clinical Neuroscience, 2017, 40, 64-66.	1.5	1
62	Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research, 2017, 23, 1841-1851.	7.0	94
63	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Communication and Signaling, 2017, 15, 34.	6.5	21
64	MEDU-03. MEDULLOBLASTOMA GENOMIC SUBGROUP-SPECIFIC OUTCOMES IN IRRADIATED CHILDREN ABOVE 3 YEARS TREATED AT KING FAHAD MEDICAL CITY (KFMC). Neuro-Oncology, 2017, 19, iv37-iv38.	1.2	0
65	PATH-03. "DEDIFFERENTIATED―GLIOBLASTOMA: AÂCLINICOPATHOLOGICAL AND MOLECULAR STUDY. Neuro-Oncology, 2017, 19, vi171-vi171.	1.2	O
66	Radiographic Prediction of Meningioma Grade and Genomic Profile. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	1
67	Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS ONE, 2017, 12, e0187908.	2.5	109
68	Genomic Landscape of High-grade Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	0
69	Decreased <scp>FOXJ1</scp> expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. Journal of Pathology, 2016, 238, 584-597.	4.5	29
70	Genomic characterization of recurrent high-grade astroblastoma. Cancer Genetics, 2016, 209, 321-330.	0.4	17
71	Genomic landscape of intracranial meningiomas. Journal of Neurosurgery, 2016, 125, 525-535.	1.6	104
72	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	1.2	221

#	Article	lF	Citations
73	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncology, 2016, 18, 269-274.	1.2	64
74	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	6.3	182
<b>7</b> 5	Cancer diagnostics: The journey from histomorphology to molecular profiling. Oncotarget, 2016, 7, 58696-58708.	1.8	37
76	MAPK activation and <i>HRAS </i> mutation identified in pituitary spindle cell oncocytoma. Oncotarget, 2016, 7, 37054-37063.	1.8	27
77	Genomic Landscape of Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2016, 77, .	0.8	О
78	Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance. Journal of Cancer, 2015, 6, 1005-1010.	2.5	16
79	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	1.8	127
80	Extracranial growth of glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1521-1523.	1.5	25
81	MNGO-01A PROGNOSTIC CYTOGENETIC SCORING SYSTEM TO GUIDE THE ADJUVANT MANAGEMENT OF PATIENTS WITH ATYPICAL MENINGIOMA. Neuro-Oncology, 2015, 17, v130.1-v130.	1.2	O
82	GENO-09LANDSCAPE OF GENOMIC ALTERATIONS IN PITUITARY ADENOMAS. Neuro-Oncology, 2015, 17, v93.1-v93.	1.2	0
83	Myelodysplastic syndrome with progressive multifocal predominantly pontine demyelination. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e90.	6.0	O
84	ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350.	0.4	73
85	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	1.2	40
86	A Prognostic Molecular Scoring System to Guide the Adjuvant Management of Patients With Gross Totally Resected Atypical Meningioma. International Journal of Radiation Oncology Biology Physics, 2015, 93, S167.	0.8	1
87	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Modern Pathology, 2015, 28, 596-606.	5.5	55
88	The Potential Role of Social Media Platforms in Community Awareness of Antibiotic Use in the Gulf Cooperation Council States: Luxury or Necessity?. Journal of Medical Internet Research, 2015, 17, e233.	4.3	32
89	Genetic Alterations in Skull Base Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2015, 76, .	0.8	O
90	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget, 2014, 5, 10596-10606.	1.8	65

#	Article	IF	CITATIONS
91	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathologica Communications, 2014, 2, 167.	5.2	65
92	Isolated cerebral mucormycosis of the basal ganglia. Clinical Neurology and Neurosurgery, 2014, 124, 102-105.	1.4	24
93	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	1.2	80
94	First report of tenosynovitis in an immunocompetent person caused by Mycobacterium heraklionense. JMM Case Reports, 2014, 1, .	1.3	8
95	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget, 2014, 5, 8083-8092.	1.8	55
96	The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Modern Pathology, 2013, 26, 1425-1432.	5.5	98
97	Radiation-induced glioma following CyberKnife $\hat{A}^{\odot}$ treatment of metastatic renal cell carcinoma: a case report. Journal of Medical Case Reports, 2012, 6, 271.	0.8	8
98	Duplication of C7orf58, WNT16 and FAM3C in an Obese Female with a t(7;22)(q32.1;q11.2) Chromosomal Translocation and Clinical Features Resembling Coffin-Siris Syndrome. PLoS ONE, 2012, 7, e52353.	2.5	5
99	Gastrointestinal stromal tumour originating from the hepatic falciform ligament. BMJ Case Reports, 2012, 2012, bcr0320126136-bcr0320126136.	0.5	9
100	CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. Journal of Hematology and Oncology, 2010, 3, 6.	17.0	68
101	Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1î±: a histologic and immunohistochemical study of 45 cases. Annals of Diagnostic Pathology, 2010, 14, 15-22.	1.3	6
102	Absence of FLT3 and JAK2 (V617F) mutations in Langerhans cell histiocytosis. Leukemia Research, 2009, 33, e173-e174.	0.8	1
103	Diagnostic Evaluation of Metastatic Placental Site Trophoblastic Tumor. Obstetrics and Gynecology, 2009, 114, 465-468.	2.4	4
104	Expression of Matrix Metalloproteinase 7 and Fibronectin in Papillary Thyroid Cancer: Gene Expression Profiling using real time PCR. FASEB Journal, 2009, 23, LB331.	0.5	0
105	Asymptomatic diffuse "encephalitic" cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature. International Journal of Clinical and Experimental Pathology, 2009, 3, 106-9.	0.5	15
106	Primary retroperitoneal mucinous cystadenoma. Journal of King Abdulaziz University, Islamic Economics, 2009, 30, 146-9.	1.1	7
107	Is a computer crossmatch in the absence of an immediateâ€spin antibody screen adequate for persons identified to be at increased risk of forming new blood group antibodies?. Transfusion, 2008, 48, 2265-2266.	1.6	2
108	Absence of FLT3 and JAK2 (V617F) Mutations in Langerhans Cell Histiocytosis. Blood, 2008, 112, 4496-4496.	1.4	0

#	Article	IF	CITATIONS
109	Leading a female research team. Nature Middle East, 0, , .	0.0	0
110	Periocular Pigmented Basal Cell Carcinomas: Clinicopathologic Features and Mutational Profile. Ophthalmic Plastic and Reconstructive Surgery, 0, Publish Ahead of Print, .	0.8	1